http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-501668-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_31fb964e2148aff14f5bfc5f5ae6fbaf http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd6d6bce7af3384674d534f52e8f7958 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-02 |
| filingDate | 1996-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_21129437eed03629fb1a294cffb674c8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9448c377317581781bcabfe343055b81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62bced34504bfe065fe08e5626d764f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3ff10cfedc86a745fb9356c52ec730c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_29f3e62edfe543fc6c653aac9e34c81d |
| publicationDate | 2001-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-501668-A |
| titleOfInvention | Use of Helicobacter antigens or an antibody specific for these antigens for the manufacture of a medicament for the treatment or prevention of Helicobacter infection |
| abstract | Use of a Helicobacter antigen selected from the group consisting of: i) an antigen having a molecular mass of approximately 19 kDa which is processed into a mature form having a molecular mass of approximately 17 kDa, the antigen comprising an amino acid sequence substantially corresponding to the deduced sequence of clone B4.6 (SEQ ID NO. 10 - described in the specification), or allelic or other variants thereof; ii) an antigen having a molecular mass of approximately 13 kDa, the antigen comprising an amino acid sequence substantially corresponding to the deduced sequence of clone C3.5 (SEQ ID NO. 2 - described in the specification), or allelic or other variants thereof; iii) an antigen having a molecular mass of approximately 36 kDa, the antigen comprising an amino acid sequence substantially corresponding to the deduced sequence of clone E2.5 (SEQ ID NO. 4 - described in the specification), or allelic or other variants thereof; iv) an antigen having a molecular mass of approximately 50 kDa, the antigen comprising an amino acid sequence substantially corresponding to the deduced sequence of clone G3.8 (SEQ ID NO. 6 - described in the specification), or allelic or other variants thereof; v) an antigen having a molecular mass of approximately 29 kDa, the antigen comprising an amino acid sequence substantially corresponding to the deduced sequence of clone H5.1 (SEQ ID NO. 8 - described in the specification), or allelic or other variants thereof; vi) immunogenic fragments of any of the antigens (i) to (v) above which are capable of eliciting a specific protective immune response in a mammalian host; together with one or more pharmaceutically acceptable carriers and/or diluents, optionally in association with an adjuvant, in the manufacture of a composition for the treatment or prevention of Helicobacter infection in a mammalian host. Also described is the use of an antibody specific for a Helicobacter antigen (selected from I -vi above), in the manufacture of a vaccine composition for the treatment or prevention of Helicobacter infection in a mammalian host. Also described is the use of a vaccine vector expressing an isolated Helicobacter antigen (selected from i - vi above), in the manufacture of a vaccine composition for the treatment or prevention of Helicobacter infection in a mammalian host. |
| priorityDate | 1995-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 646.